ERBB2 and neoplasm: Furthermore, the cleavable linker of Disitamab Vedotin enables anti-tumor activity towards HER2-negative tumor cells through the bystander effect, which might overcome resistance caused by the heterogeneity of HER2 expression levels among tumor cells [10, 12].